Research Letters |

Management of Fingolimod-Associated Macular Edema

Jeanie Chui, MBBS, PhD; Geoffrey K. Herkes, MBBS, PhD; Andrew Chang, MBBS, PhD
JAMA Ophthalmol. 2013;131(5):694-696. doi:10.1001/jamaophthalmol.2013.47.
Text Size: A A A
Published online


Fingolimod is the first orally active drug approved for the management of relapsing-remitting multiple sclerosis (MS).1 Its immunosuppressive action is related to downregulation of sphingosine 1–phosphate receptor 1 on lymphocytes, which inhibits their egress from lymphoid tissues.2 Macular edema (ME) is an infrequent adverse effect of fingolimod, usually occurring within 3 months of initiation of treatment and resolving on cessation of fingolimod.1 We report a case of ME in a patient with MS receiving fingolimod and its successful management by topical anti-inflammatory drugs.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure 1. Optical coherence tomographic images showing cystoid macular edema initially affecting the right eye (OD) at week 0, which improved on treatment with topical dexamethasone and ketorolac tromethamine. At week 4, topical treatment was extended to the previously untreated left eye (OS), which had begun to display cystic changes. Macular edema improved after topical treatment was increased to every 2 hours at week 23. At week 35, 5 weeks after cessation of fingolimod use, macular edema had completely resolved.

Place holder to copy figure label and caption
Graphic Jump Location

Figure 2. Fundus photographs (A) and fluorescein angiograms (B) of the right (OD) and left (OS) eyes 1 month after commencing topical treatment with anti-inflammatory drugs. Late-phase fluorescein leakage is observed in the left macula.




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles